SciSparc subsidiary NeuroThera pursues FDA orphan drug designation for Tourette drug SCI-110

PUBT · 2d ago
SciSparc subsidiary NeuroThera pursues FDA orphan drug designation for Tourette drug SCI-110
  • SciSparc subsidiary NeuroThera Labs began pursuing FDA orphan drug designation for SCI-110 in adult Tourette syndrome.
  • NeuroThera hired RK Strategies to support the US regulatory push, stakeholder outreach, market access positioning.
  • SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dose.
  • Phase IIb program underway at three academic centers; Phase IIa showed 21% average tic reduction on YGTSS Total Tic Score.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020817PRIMZONEFULLFEED9820261) on September 02, 2026, and is solely responsible for the information contained therein.